Effect of carnosine, aminoguanidine, and aspirin drops on the prevention of cataracts in diabetic rats

Molecular Vision

Volumn 14, Issue , 2008, Pages 2282-2291

  Yan, Hong ^a   Guo, Yong ^a   Zhang, Jie ^a   Ding, Zhenghua ^a   Ha, Wenjing ^a   Harding, J J ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; CARNOSINE; CATALASE; GLUTATHIONE; GLUTATHIONE REDUCTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATARACT; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; RAT; SLIT LAMP; STREPTOZOCIN DIABETES;

ANIMALS; ASPIRIN; BLOOD GLUCOSE; BODY WEIGHT; CARNOSINE; CATARACT; CORNEA; DIABETES MELLITUS, EXPERIMENTAL; DISEASE PROGRESSION; EYE PROTEINS; GLYCOSYLATION; GUANIDINES; LENS, CRYSTALLINE; MALE; OPHTHALMIC SOLUTIONS; RATS; RATS, SPRAGUE-DAWLEY; STAINING AND LABELING; STREPTOZOCIN;

EID: 57749198879     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Harding JJ. Cataract: biochemistry, epidemiology and pharmacology. London: Chapman and Hall; 1991. p. 83-107.
2. Brian G, Taylor H. Cataract blindness-challenges for the 21st century. Bull World Health Organ 2001; 79:249-56.
3. Harding JJ. Viewing molecular mechanisms of ageing through a lens. Ageing Res Rev 2002; 1:465-79.
4. Blakytny R, Harding JJ. Glycation (non-enzymic glycosylation) inactivates glutathione reductase. Biochem J 1992; 288:303-7.
5. Hook DW, Harding JJ. The effect of modification of alpha-crystallin by prednisolone-21-hemisuccinate and fructose 6-phosphate on chaperone activity. Dev Ophthalmol 2002; 35:150-60.
6. Yan H, Harding JJ. Glycation-induced inactivation and loss of antigenicity of catalase and superoxide dismutase. Biochem J 1997; 328:599-605.
7. Yan H, Harding JJ. Carnosine inhibits modifications and decreased molecular chaperone activity of lens alpha-crystallin induced by ribose and fructose 6-phosphate. Mol Vis 2006; 12:205-14.
8. Harding JJ, Ganea E. Protection against glycation and similar post-translational modifications of proteins. Biochim Biophys Acta 2006; 1764:1436-46.
9. Toh T, Morton J, Coxon J, Elder MJ. Medical treatment of cataract. Clin Experiment Ophthalmol 2007; 35:664-71.
10. Hipkiss AR, Michaelis J, Syrris P. Non-enzymatic glycosylation of the dipeptide L-carnosine, a potential anti-protein-cross-linking agent. FEBS Lett 1995; 371:81-5.
11. Seidler NW, Shokry SS, Nauth J. Properties of a glycation product derived from carnosine. J Biochem Mol Biol Biophys 2001; 5:153-62.
12. Hipkiss AR, Brownson C, Carrier MJ. Carnosine, the anti-ageing, anti-oxidant dipeptide, may react with protein carbonyl groups. Mech Ageing Dev 2001; 122:1431-45.
13. Hobart LJ, Seibel I, Yeargans GS, Seidler NW. Anti-crosslinking properties of carnosine: significance of histidine. Life Sci 2004; 75:1379-89.
14. Babizhayev MA, Deyev AI, Yermakova VN, Semiletov YA, Davydova NG, Kurysheva NI, Zhukotskii AV, Goldman IM. N-Acetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts. Peptides 2001; 22:979-94.
15. Seidler NW, Yeargans GS, Morgan TG. Carnosine disaggregates glycated α-crystallin: an in vitro study. Arch Biochem Biophys 2004; 427:110-5.
16. Ukeda H, Hasegawa Y, Harada Y, Sawamura M. Effect of carnosine and related compounds on the inactivation of human Cu, Zn-superoxide dismutase by modification of fructose and glycolaldehyde. Biosci Biotechnol Biochem 2002; 66:36-43.
17. Yan H, Harding JJ. Carnosine protects against the inactivation of esterase induced by glycation and a steroid. Biochim Biophys Acta 2005; 1741:120-6.
18. Yan H, Harding JJ. Protective effect of carnosine against inactivation of enzymes induced by glycation and a steroid: relevance to cataract. Am J Ophthalmol 2005; 139:S55.
19. Brownson C, Hipkiss AR. Carnosine reacts with a glycated protein. Free Radic Biol Med 2000; 28:1564-70.
20. Babizhayev MA, Deyev AI, Yermakova VN, Brikman IV, Bours J. Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes. Drugs R D 2004; 5:125-39.
21. Guo Y, Yan H. Preventive effect of carnosine on cataract development. Yan Ke Xue Bao 2006; 22:85-8.
22. Williams DL, Munday P. The effect of a topical antioxidant formulation including N-acetyl carnosine on canine cataract: a preliminary study. Vet Ophthalmol 2006; 9:311-6.
23. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes induced arterial wall protein cross linking. Science 1986; 232:1629-32.
24. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 1991; 88:11555-8.
25. Yagihashi S, Kamijo M, Baba M, Nagai K. Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 1992; 41:47-52.
26. Swamy-Mruthinti S, Green K, Abraham EC. Inhibition of cataracts in moderately diabetic rats by aminoguanidine. Exp Eye Res 1996; 62:505-12.
27. Ajiboye R, Harding JJ. The non-enzymic glycosylation of bovine lens proteins by glucosamine and its inhibition by aspirin, ibuprofen and glutathione. Exp Eye Res 1989; 49:31-41.
28. Kumari K, Umar S, Bansal V, Sahib MK. Inhibition of diabetes associated complications by nucleophilic compounds. Diabetes 1991; 40:1079-84.
29. Agardh E, Hultberg B, Agardh C. Effects of inhibition of glycation and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats. Curr Eye Res 2000; 21:543-9.
30. Nabekura T, Koizumi Y, Nakao M, Tomohiro M, Inomata M, Ito Y. Delay of cataract development in hereditary cataract UPL rats by disulfiram and aminoguanidine. Exp Eye Res 2003; 76:169-74.
31. Blakytny R, Harding JJ. Prevention of cataract in diabetic rats by aspirin, paracetamol (acetaminophen) and ibuprofen. Exp Eye Res 1992; 54:509-18.
32. Harding JJ. Can drugs or micronutrients prevent cataract? Drugs Aging 2001; 18:473-86.
33. Wegener A. Cataract prevention: Therapeutic approaches and critical review of current status. Ophthalmologe 2003; 100:176-80.
34. Yan H, Wang J, Liu B, Shang L. Protective effect of aspirin against dexamethasone-induced cataract in cultured rat lens. Ophthalmic Res 2006; 38:303-8.
35. Zhang S, Chai FY, Yan H, Guo Y, Harding JJ. Effects of N-acetylcysteine and glutathione ethyl ester drops on streptozotocin-induced diabetic cataract in rats. Mol Vis 2008; 14:862-70.
36. Wander AH, Centifanto YM, Kaufman HE. Strain specificity of clinical isolates of herpes simplex virus. Arch Ophthalmol 1980; 98:1458-61.
37. Harding JJ. Free and protein-bound glutathione in normal and cataractous human lenses. Biochem J 1970; 117:957-60.
38. Gupta SK, Joshi S, Tandon R, Mathur P. Topical aspirin provides protection against galactosemic cataract. Indian J Ophthalmol 1997; 45:221-5.
39. Janoria KG, Gunda S, Boddu SH, Mitra AK. Novel approaches to retinal drug delivery. Expert Opin Drug Deliv 2007; 4:371-88.